<?xml version="1.0" encoding="UTF-8"?>
<p>Cushing’s syndrome is an orphan disease that affects a minute population. The development of this disease occurs due to the prolonged exposure to glucocorticoids such as cortisol, which decimates the normal biological systems of the body. The most profound symptoms can range from excessive weight gain to dreadful acne, constant anxiety, hirsutism and insomnia [
 <xref rid="B65-viruses-12-01058" ref-type="bibr">65</xref>]. The drug Korlym has successfully addressed this disease. Korlym is a repurposed drug approved in the 2012, where it was intended for abortion with the active ingredient, mifepristone which, is now considered a remedy for Cushing’s syndrome. In 2018, The Washington Post had interviewed a 40-year-old Georgia resident who suffered from Cushing’s syndrome. The drug Korlym helped this patient by blocking their body’s ability to process cortisol, thus relieving the disease’s symptoms. Korlym’s legacies have led to the development of an enhanced successor subtracting the side-effects, namely Relacorilant, a highly selective glucocorticoid receptor antagonist [
 <xref rid="B66-viruses-12-01058" ref-type="bibr">66</xref>]. Relacorilant is now also in phase-I clinical trials for hormone-resistant prostate cancer [
 <xref rid="B67-viruses-12-01058" ref-type="bibr">67</xref>]. 
</p>
